BIO
The mRNA field has evolved rapidly in recent years, paving the way for greater innovation across the advanced therapy medicinal products (ATMP) space. Staying at the forefront of this evolution requires pharmaceutical companies to make the necessary changes to their leadership and business offerings to keep up with technological advancements and meet the needs of patients.
At Recipharm, this has been no less important. Vikas Gupta, Head of our biologics business unit ReciBioPharm, recently shared some of his short- and long-term ambitions for the company and discussed the importance of continuous innovation in driving the industry forward.
In this interview, he shared his insights into:
1. Key priorities for ReciBioPharm
Since taking the role of Head of ReciBioPharm, Gupta’s primary focus has been on:
- Integrating the three companies acquired in 2022 — Arranta Bio, Vibalogics and GenIbet — to form a new biologics unit dedicated to the fast-evolving ATMP space
- Establishing Centers of Excellence across North America and Europe by focusing on core competencies and knowledge transfer
- Becoming the preferred partner for advanced therapy pioneers, providing innovative solutions across development, manufacturing and analytics
2. Enhancing manufacturing through research
Our commitment to enhancing manufacturing through research goes beyond solving technical challenges for clients; we actively participate in projects that utilise the latest technologies and innovations to reduce design space and enhance machine learning capabilities for predictive and feedback controls. Working with world-leading organisations, our goal is to develop a solution capable of manufacturing up to 240 million doses of an xRNA-based vaccine, which can be rapidly deployed worldwide in the event of a pandemic outbreak.
3. Post-COVID-19 challenges and how we’re overcoming them
The post-COVID-19 landscape highlighted a disparity in the required experience, scale and capacity to meet the needs of the ATMP market. These challenges require us to take a fresh approach to meet our clients’ needs, and we are ensuring that the right leadership behaviour is modelled both internally and across our client interactions.
Read more of Gupta’s answers in the full Life Sciences Review piece by clicking the button below: